Drugs / FLYSYN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02789254 | Feb 2017 → Sep 2021 | acute myeloid leukemia | Synimmune GmbH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLYSYN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02789254 ↗ |
| Action | Deplete | “FLYSYN is an Fc-optimized antibody for eradication of MRD directed to FLT3/CD135” PMID 37587502 ↗ Aug 2023 |
| Route | Intravenous | “administered intravenously” PMID 37587502 ↗ Aug 2023 |
| Target | FLT3 | “directed to FLT3/CD135” PMID 37587502 ↗ Aug 2023 |